Functions of AAV-CMV-F.IX And AAV-EF1α-F.IX in Gene Therapy for Hemophilia B

There has been substantial progress in using gene therapy to treat animals with hemophilia. Adeno-associated viral (AAV) gene transfer of coagulation factor IX to skeletal muscle and liver of murine and canine models of hemophilia has resulted in sustained systemic expression and, in several studies, in complete cure of the bleeding disorder. Two AAV vectors widely used at present are AAV-CMV-F.IX and AAV-EF1α-F.IX. This work compares the predicted molecular functions of AAV-CMV-F.IX and AAV-EF1α -F.IX by sequence docking and gene ontology. It is shown that both AAV-CMV-F.IX and AAV-EF1α -F.IX induce coagulation factor IXa activity; however, AAV-CMV-F.IX administration also yields coagulation factor XIa activity and AAV-EF1α -F.IX treatment results in coagulation factor Xa activity. Therefore, AAV-CMV-F.IX might be useful for factor XI deficiency. AAV-CMV-F.IX has several additional molecular functions and processes compared with AAV-CMV-F.IX.